Kinesin-1 is a dynamic heterotetrameric assembly of two heavy and two light chains (KHC and KLC) that mediates microtubule-based intracellular transport of many different cargoes. The complex adopts a ...
These subgroup insights will guide trial design, patient selection, and endpoint strategy for Autonomix's upcoming U.S.-based multicenter clinical study, currently planned to begin in 2026, which will ...
EORTC QLQ-C30 subgroup results confirm broad and durable quality-of-life improvements across disease stages and metastasis status, complementing ...
The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...
The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.
The autoimmune disorder destroys the body’s ability to produce insulin. Some patients in experimental trials have gotten it ...
Cadmus C. Rich, MD, MBA, as Chief Medical Officer, and Carlos Quezada-Ruiz, MD, FASRS, as Chair of the Scientific Advisory Board, bring ...
Royce. With its orange leather seats and cushions embroidered with the logo of his aesthetic clinic, the limo is worth well ...
Detailed price information for Kalaris Therapeutics Inc (KLRS-Q) from The Globe and Mail including charting and trades.
Guild Wars Reforged releases on Dec. 2, costing $19.99 for new players, revitalizing the original 2005 Guild Wars.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback